Cargando…

Development and Validation of a DeepSurv Nomogram to Predict Survival Outcomes and Guide Personalized Adjuvant Chemotherapy in Non-Small Cell Lung Cancer

OBJECTIVE: To develop and validate a DeepSurv nomogram based on radiomic features extracted from computed tomography images and clinicopathological factors, to predict the overall survival and guide individualized adjuvant chemotherapy in patients with non-small cell lung cancer (NSCLC). PATIENTS AN...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Bin, Liu, Chengxing, Wu, Ren, Zhong, Jing, Li, Ang, Ma, Lu, Zhong, Jian, Yin, Saisai, Zhou, Changsheng, Ge, Yingqian, Tao, Xinwei, Zhang, Longjiang, Lu, Guangming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260694/
https://www.ncbi.nlm.nih.gov/pubmed/35814402
http://dx.doi.org/10.3389/fonc.2022.895014
_version_ 1784742094031552512
author Yang, Bin
Liu, Chengxing
Wu, Ren
Zhong, Jing
Li, Ang
Ma, Lu
Zhong, Jian
Yin, Saisai
Zhou, Changsheng
Ge, Yingqian
Tao, Xinwei
Zhang, Longjiang
Lu, Guangming
author_facet Yang, Bin
Liu, Chengxing
Wu, Ren
Zhong, Jing
Li, Ang
Ma, Lu
Zhong, Jian
Yin, Saisai
Zhou, Changsheng
Ge, Yingqian
Tao, Xinwei
Zhang, Longjiang
Lu, Guangming
author_sort Yang, Bin
collection PubMed
description OBJECTIVE: To develop and validate a DeepSurv nomogram based on radiomic features extracted from computed tomography images and clinicopathological factors, to predict the overall survival and guide individualized adjuvant chemotherapy in patients with non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: This retrospective study involved 976 consecutive patients with NSCLC (training cohort, n=683; validation cohort, n=293). DeepSurv was constructed based on 1,227 radiomic features, and the risk score was calculated for each patient as the output. A clinical multivariate Cox regression model was built with clinicopathological factors to determine the independent risk factors. Finally, a DeepSurv nomogram was constructed by integrating the risk score and independent clinicopathological factors. The discrimination capability, calibration, and clinical usefulness of the nomogram performance were assessed using concordance index evaluation, the Greenwood-Nam-D’Agostino test, and decision curve analysis, respectively. The treatment strategy was analyzed using a Kaplan–Meier curve and log-rank test for the high- and low-risk groups. RESULTS: The DeepSurv nomogram yielded a significantly better concordance index (training cohort, 0.821; validation cohort 0.768) with goodness-of-fit (P<0.05). The risk score, age, thyroid transcription factor-1, Ki-67, and disease stage were the independent risk factors for NSCLC.The Greenwood-Nam-D’Agostino test showed good calibration performance (P=0.39). Both high- and low-risk patients did not benefit from adjuvant chemotherapy, and chemotherapy in low-risk groups may lead to a poorer prognosis. CONCLUSIONS: The DeepSurv nomogram, which is based on the risk score and independent risk factors, had good predictive performance for survival outcome. Further, it could be used to guide personalized adjuvant chemotherapy in patients with NSCLC.
format Online
Article
Text
id pubmed-9260694
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92606942022-07-08 Development and Validation of a DeepSurv Nomogram to Predict Survival Outcomes and Guide Personalized Adjuvant Chemotherapy in Non-Small Cell Lung Cancer Yang, Bin Liu, Chengxing Wu, Ren Zhong, Jing Li, Ang Ma, Lu Zhong, Jian Yin, Saisai Zhou, Changsheng Ge, Yingqian Tao, Xinwei Zhang, Longjiang Lu, Guangming Front Oncol Oncology OBJECTIVE: To develop and validate a DeepSurv nomogram based on radiomic features extracted from computed tomography images and clinicopathological factors, to predict the overall survival and guide individualized adjuvant chemotherapy in patients with non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: This retrospective study involved 976 consecutive patients with NSCLC (training cohort, n=683; validation cohort, n=293). DeepSurv was constructed based on 1,227 radiomic features, and the risk score was calculated for each patient as the output. A clinical multivariate Cox regression model was built with clinicopathological factors to determine the independent risk factors. Finally, a DeepSurv nomogram was constructed by integrating the risk score and independent clinicopathological factors. The discrimination capability, calibration, and clinical usefulness of the nomogram performance were assessed using concordance index evaluation, the Greenwood-Nam-D’Agostino test, and decision curve analysis, respectively. The treatment strategy was analyzed using a Kaplan–Meier curve and log-rank test for the high- and low-risk groups. RESULTS: The DeepSurv nomogram yielded a significantly better concordance index (training cohort, 0.821; validation cohort 0.768) with goodness-of-fit (P<0.05). The risk score, age, thyroid transcription factor-1, Ki-67, and disease stage were the independent risk factors for NSCLC.The Greenwood-Nam-D’Agostino test showed good calibration performance (P=0.39). Both high- and low-risk patients did not benefit from adjuvant chemotherapy, and chemotherapy in low-risk groups may lead to a poorer prognosis. CONCLUSIONS: The DeepSurv nomogram, which is based on the risk score and independent risk factors, had good predictive performance for survival outcome. Further, it could be used to guide personalized adjuvant chemotherapy in patients with NSCLC. Frontiers Media S.A. 2022-06-23 /pmc/articles/PMC9260694/ /pubmed/35814402 http://dx.doi.org/10.3389/fonc.2022.895014 Text en Copyright © 2022 Yang, Liu, Wu, Zhong, Li, Ma, Zhong, Yin, Zhou, Ge, Tao, Zhang and Lu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Yang, Bin
Liu, Chengxing
Wu, Ren
Zhong, Jing
Li, Ang
Ma, Lu
Zhong, Jian
Yin, Saisai
Zhou, Changsheng
Ge, Yingqian
Tao, Xinwei
Zhang, Longjiang
Lu, Guangming
Development and Validation of a DeepSurv Nomogram to Predict Survival Outcomes and Guide Personalized Adjuvant Chemotherapy in Non-Small Cell Lung Cancer
title Development and Validation of a DeepSurv Nomogram to Predict Survival Outcomes and Guide Personalized Adjuvant Chemotherapy in Non-Small Cell Lung Cancer
title_full Development and Validation of a DeepSurv Nomogram to Predict Survival Outcomes and Guide Personalized Adjuvant Chemotherapy in Non-Small Cell Lung Cancer
title_fullStr Development and Validation of a DeepSurv Nomogram to Predict Survival Outcomes and Guide Personalized Adjuvant Chemotherapy in Non-Small Cell Lung Cancer
title_full_unstemmed Development and Validation of a DeepSurv Nomogram to Predict Survival Outcomes and Guide Personalized Adjuvant Chemotherapy in Non-Small Cell Lung Cancer
title_short Development and Validation of a DeepSurv Nomogram to Predict Survival Outcomes and Guide Personalized Adjuvant Chemotherapy in Non-Small Cell Lung Cancer
title_sort development and validation of a deepsurv nomogram to predict survival outcomes and guide personalized adjuvant chemotherapy in non-small cell lung cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260694/
https://www.ncbi.nlm.nih.gov/pubmed/35814402
http://dx.doi.org/10.3389/fonc.2022.895014
work_keys_str_mv AT yangbin developmentandvalidationofadeepsurvnomogramtopredictsurvivaloutcomesandguidepersonalizedadjuvantchemotherapyinnonsmallcelllungcancer
AT liuchengxing developmentandvalidationofadeepsurvnomogramtopredictsurvivaloutcomesandguidepersonalizedadjuvantchemotherapyinnonsmallcelllungcancer
AT wuren developmentandvalidationofadeepsurvnomogramtopredictsurvivaloutcomesandguidepersonalizedadjuvantchemotherapyinnonsmallcelllungcancer
AT zhongjing developmentandvalidationofadeepsurvnomogramtopredictsurvivaloutcomesandguidepersonalizedadjuvantchemotherapyinnonsmallcelllungcancer
AT liang developmentandvalidationofadeepsurvnomogramtopredictsurvivaloutcomesandguidepersonalizedadjuvantchemotherapyinnonsmallcelllungcancer
AT malu developmentandvalidationofadeepsurvnomogramtopredictsurvivaloutcomesandguidepersonalizedadjuvantchemotherapyinnonsmallcelllungcancer
AT zhongjian developmentandvalidationofadeepsurvnomogramtopredictsurvivaloutcomesandguidepersonalizedadjuvantchemotherapyinnonsmallcelllungcancer
AT yinsaisai developmentandvalidationofadeepsurvnomogramtopredictsurvivaloutcomesandguidepersonalizedadjuvantchemotherapyinnonsmallcelllungcancer
AT zhouchangsheng developmentandvalidationofadeepsurvnomogramtopredictsurvivaloutcomesandguidepersonalizedadjuvantchemotherapyinnonsmallcelllungcancer
AT geyingqian developmentandvalidationofadeepsurvnomogramtopredictsurvivaloutcomesandguidepersonalizedadjuvantchemotherapyinnonsmallcelllungcancer
AT taoxinwei developmentandvalidationofadeepsurvnomogramtopredictsurvivaloutcomesandguidepersonalizedadjuvantchemotherapyinnonsmallcelllungcancer
AT zhanglongjiang developmentandvalidationofadeepsurvnomogramtopredictsurvivaloutcomesandguidepersonalizedadjuvantchemotherapyinnonsmallcelllungcancer
AT luguangming developmentandvalidationofadeepsurvnomogramtopredictsurvivaloutcomesandguidepersonalizedadjuvantchemotherapyinnonsmallcelllungcancer